Japan Research Foundation of Prediction, Diagnosis and Therapy for Gastric Cancer (JRF PDT GC), Tokyo, Japan.
Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(7):405-14. doi: 10.2183/pjab.87.405.
The current status of screening for gastric cancer-risk (gastritis A, B, C, D) method using combined assay for serum anti-Helicobacter pylori (Hp) IgG antibody and serum pepsinogen (PG) levels, "ABC method", was reviewed and the latest results of our ongoing trial are reported. It was performed using the following strategy: Subjects were classified into 1 of 4 risk groups based on the results of the two serologic tests, anti-Hp IgG antibody titers and the PG I and II levels: Group A [Hp(-)PG(-)], infection-free subjects; Group B [Hp(+)PG(-)], chronic atrophic gastritis (CAG) free or mild; Group C [Hp(+)PG(+)], CAG; Group D [Hp(-)PG(+)]), severe CAG with extensive intestinal metaplasia. Continuous endoscopic follow-up examinations are required to detect early stages of gastric cancer. Asymptomatic Group A, which accounts for 50-80% of all the subjects may be excluded from the secondary endoscopic examination, from the viewpoint of efficiency. Hp-infected subjects should be administered eradication treatment aimed at the prevention of gastric cancer.
目前，使用联合检测血清抗幽门螺杆菌（Hp）IgG 抗体和血清胃蛋白酶原（PG）水平的方法对胃癌风险（胃炎 A、B、C、D）进行筛查，被称为“ABC 法”，我们对其现状进行了综述，并报告了正在进行的试验的最新结果。该方法采用以下策略：根据两项血清学检测结果，即抗 Hp IgG 抗体滴度和 PG I 和 II 水平，将受试者分为 4 个风险组之一：A 组 [Hp（-）PG（-）]，无感染受试者；B 组 [Hp（+）PG（-）]，无慢性萎缩性胃炎（CAG）或轻度 CAG；C 组 [Hp（+）PG（+）]，CAG；D 组 [Hp（-）PG（+）]，伴有广泛肠化生的严重 CAG。需要进行连续的内镜随访检查以发现胃癌的早期阶段。从效率的角度来看，无症状的 A 组（占所有受试者的 50-80%）可能被排除在二级内镜检查之外。应针对胃癌预防对 Hp 感染的受试者进行根除治疗。
